Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
|
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 50 条
  • [1] Safety Assessment of an Anti-Obesity Drug (Sibutramine) A Retrospective Cohort Study
    Tyczynski, Jerzy E.
    Oleske, Denise M.
    Klingman, David
    Ferrufino, Cheryl P.
    Lee, Won Chan
    DRUG SAFETY, 2012, 35 (08) : 629 - 644
  • [2] Safety pharmacology of sibutramine mesylate, an anti-obesity drug
    Kim, EJ
    Park, EK
    Suh, KH
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2005, 24 (03) : 109 - 119
  • [3] The discovery and status of sibutramine as an anti-obesity drug
    Luque, CA
    Rey, JA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) : 119 - 128
  • [4] Metabolism of anti-obesity drug sibutramine in primary cultures of rat hepatocytes
    Hakala, KS
    Link, M
    Szotakova, B
    Skalova, L
    Kostiainen, R
    Ketola, R
    DRUG METABOLISM REVIEWS, 2005, 37 : 41 - 42
  • [5] Sibutramine: current status as an anti-obesity drug and its future perspectives
    Sharma, Bikash
    Henderson, David C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (12) : 2161 - 2173
  • [6] Assessment of redox state and biochemical parameters of salivary glands in rats treated with anti-obesity drug sibutramine hydrochloride
    Damáris Raissa dos Santos
    Gabriela Alice Fiais
    Henrique Arnaldo Oliveira
    Tayná Buffulin Ribas
    Rayne Oliveira Souza
    Thaís Verônica Saori Tsosura
    Doris Hissako Matsushita
    Edilson Ervolino
    Rita Cássia Menegati Dornelles
    Ana Cláudia de Melo Stevanato Nakamune
    Antonio Hernandes Chaves-Neto
    Clinical Oral Investigations, 2022, 26 : 5833 - 5846
  • [7] Assessment of redox state and biochemical parameters of salivary glands in rats treated with anti-obesity drug sibutramine hydrochloride
    dos Santos, Damaris Raissa
    Fiais, Gabriela Alice
    Oliveira, Henrique Arnaldo
    Ribas, Tayna Buffulin
    Souza, Rayne Oliveira
    Saori Tsosura, Thais Veronica
    Matsushita, Doris Hissako
    Ervolino, Edilson
    Menegati Dornelles, Rita Cassia
    de Melo Stevanato Nakamune, Ana Claudia
    Chaves-Neto, Antonio Hernandes
    CLINICAL ORAL INVESTIGATIONS, 2022, 26 (09) : 5833 - 5846
  • [8] Sibutramine: A review of the pharmacology of a novel anti-obesity agent
    Stock, MJ
    INTERNATIONAL JOURNAL OF OBESITY, 1997, 21 : S25 - S29
  • [9] THE IMPACT OF APPROVED ANTI-OBESITY MEDICATIONS ON OSTEOARTHRITIS RISK IN PATIENTS WITH OBESITY: A RETROSPECTIVE COHORT STUDY
    Baser, O.
    Isenman, L.
    Samayoa, G.
    Dwivedi, A.
    Baser, E.
    Baser, S.
    VALUE IN HEALTH, 2024, 27 (06) : S45 - S45
  • [10] Niclosamide as an anti-obesity drug: an experimental study
    Al-Gareeb, Ali I.
    Aljubory, Khalid D.
    Alkuraishy, Hayder M.
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2017, 22 (02) : 339 - 344
12345